GEN inCode Announces Major UK Collaboration With Royal Brompton and Harefield Hospitals
USA - English
Share this article
Share this article
OXFORD, England, April 28, 2021 /PRNewswire/ GEN inCode UK Limited, the cardiovascular disease company focused on predictive genetics for the prevention of cardiovascular disease, announces today a collaboration with Royal Brompton and Harefield hospitals ( RB&H ), recently merged with Guy s and St Thomas NHS Foundation Trust ( GSTT ), to provide globally leading cardiovascular disease clinical genetic testing and reporting.
GEN inCode specializes in polygenic risk assessment for the onset of cardiovascular disease (CVD), and hence the ability to help predict and prevent future cardiovascular events. CVD is a broad disease classification which encompasses conditions such as coronary artery disease (causing angina, heart attacks, heart failure), cerebrovascular disease (causing stroke, and some dementia), peripheral vascular disease (cau